The value of real world data is frequently debated. This is very much dependent on the perspective of the person who is reviewing the data.

The German landscape for introduction of new technologies and drugs is changing dramatic. For drugs, the introduction of the Amnog process has been a drastic change. Now the medical devices are undergoing a similar drastic change, where new medical technologies coming to market through the innovation funding pathway have to go through a benefit assessment.